

Baek-Yeol Ryoo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6727448/publications.pdf>

Version: 2024-02-01

186
papers

8,314
citations

108046

37
h-index

62345

84
g-index

196
all docs

196
docs citations

196
times ranked

9085
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk of Hepatitis B Virus Reactivation in Patients Treated With Immunotherapy for Anti-cancer Treatment. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 898-907.	2.4	29
2	Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2022, 11, 38-47.	4.2	20
3	A Phase II Study to Compare the Safety and Efficacy of Direct Oral Anticoagulants versus Subcutaneous Dalteparin for Cancer-Associated Venous Thromboembolism in Patients with Advanced Upper Gastrointestinal, Hepatobiliary and Pancreatic Cancer: PRIORITY. <i>Cancers</i> , 2022, 14, 559.	1.7	10
4	Clinical relevance of adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma who underwent surgery following neoadjuvant modified FOLFIRINOX.. <i>Journal of Clinical Oncology</i> , 2022, 40, 546-546.	0.8	0
5	Regorafenib plus nivolumab as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Multicenter phase 2 trial (RENOBATE).. <i>Journal of Clinical Oncology</i> , 2022, 40, 415-415.	0.8	3
6	Efficacy and safety of lenvatinib in patients with recurrent hepatocellular carcinoma after liver transplantation: A retrospective analysis.. <i>Journal of Clinical Oncology</i> , 2022, 40, 410-410.	0.8	0
7	Adjuvant gemcitabine (GEM) versus gemcitabine plus capecitabine (GEMCAP) in resected pancreatic adenocarcinoma: A retrospective analysis.. <i>Journal of Clinical Oncology</i> , 2022, 40, 547-547.	0.8	0
8	Stereotactic Body Radiation Therapy versus Concurrent Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Propensity Score-Matched Analysis. <i>Cancers</i> , 2022, 14, 1166.	1.7	3
9	Real-world outcomes of adjuvant gemcitabine <i>versus</i> gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210971.	1.4	1
10	Real-world efficacy and safety of cabozantinib in Korean patients with advanced hepatocellular carcinoma: a multicenter retrospective analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210979.	1.4	7
11	Adjuvant gemcitabine plus cisplatin (GemCis) versus capecitabine (CAP) in patients (pts) with resected lymph node (LN)-positive extrahepatic cholangiocarcinoma (CCA): A multicenter, open-label, randomized, phase 2 study (STAMP).. <i>Journal of Clinical Oncology</i> , 2022, 40, 4019-4019.	0.8	10
12	Health-related quality of life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240. <i>Cancer</i> , 2021, 127, 865-874.	2.0	20
13	Multiparametric MRI for prediction of treatment response to neoadjuvant FOLFIRINOX therapy in borderline resectable or locally advanced pancreatic cancer. <i>European Radiology</i> , 2021, 31, 864-874.	2.3	8
14	Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study. <i>Liver Cancer</i> , 2021, 10, 107-114.	4.2	66
15	Efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin after progression on conventional irinotecan-containing chemotherapy for metastatic pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 382-382.	0.8	0
16	ALBI score and outcomes in patients with hepatocellular carcinoma: <i>post hoc</i> analysis of the randomized controlled trial KEYNOTE-240. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110399.	1.4	7
17	Clinical outcomes of liposomal irinotecan plus fluorouracil/leucovorin for metastatic pancreatic adenocarcinoma in patients previously treated with conventional irinotecan-containing chemotherapy. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110030.	1.4	9
18	Clinical outcomes of systemic therapy in patients with unresectable or metastatic combined hepatocellular&cholangiocarcinoma. <i>Liver International</i> , 2021, 41, 1398-1408.	1.9	22

#	ARTICLE	IF	CITATIONS
19	Sequential Treatment of Sorafenibâ€“Regorafenib Versus Sorafenibâ€“Physicianâ€™s Choice: A Propensity Score-Matched Analysis. <i>Targeted Oncology</i> , 2021, 16, 401-410.	1.7	5
20	Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3665-3671.	1.2	12
21	Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA). <i>Journal of Clinical Oncology</i> , 2021, 39, 1108-1118.	0.8	67
22	Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors in Korea: Literature Review and Expert Opinion. <i>Cancer Research and Treatment</i> , 2021, 53, 291-300.	1.3	8
23	Current Status and Future Perspectives of Perioperative Therapy for Resectable Biliary Tract Cancer: A Multidisciplinary Review. <i>Cancers</i> , 2021, 13, 1647.	1.7	10
24	Adjuvant Chemotherapy for Resected Ampulla of Vater Carcinoma: Retrospective Analysis of 646 Patients. <i>Cancer Research and Treatment</i> , 2021, 53, 424-435.	1.3	6
25	Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial. <i>Liver Cancer</i> , 2021, 10, 275-284.	4.2	29
26	Prognostic Value of 18F-FDG PET in Neuroendocrine Neoplasm. <i>Clinical Nuclear Medicine</i> , 2021, 46, 723-731.	0.7	10
27	Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression. <i>British Journal of Cancer</i> , 2021, 125, 200-208.	2.9	22
28	Kinetics of the neutrophilâ€“lymphocyte ratio during PDâ€“1 inhibition as a prognostic factor in advanced hepatocellular carcinoma. <i>Liver International</i> , 2021, 41, 2189-2199.	1.9	26
29	Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with regorafenib. <i>Hepatology Research</i> , 2021, 51, 796-802.	1.8	4
30	Capecitabine plus temozolomide in patients with grade 3 unresectable or metastatic gastroenteropancreatic neuroendocrine neoplasms with Ki-67 index $\geq 5\%$: single-arm phase II study. <i>ESMO Open</i> , 2021, 6, 100119.	2.0	19
31	Radiation therapy for recurrent extrahepatic bile duct cancer. <i>PLoS ONE</i> , 2021, 16, e0253285.	1.1	2
32	Efficacy and Safety Results from a Phase 2, Randomized, Double-Blind Study of Enzalutamide Versus Placebo in Advanced Hepatocellular Carcinoma. <i>Clinical Drug Investigation</i> , 2021, 41, 795-808.	1.1	4
33	Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: Results of an international, singleâ€“arm, phase 2 study. <i>Cancer</i> , 2021, 127, 4585-4593.	2.0	7
34	Metabolic activity by FDG-PET/CT after neoadjuvant chemotherapy in borderline resectable and locally advanced pancreatic cancer and association with survival. <i>British Journal of Surgery</i> , 2021, 109, 61-70.	0.1	13
35	PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 2903-2913.	0.8	154
36	Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience. <i>Targeted Oncology</i> , 2021, 16, 653-661.	1.7	0

#	ARTICLE	IF	CITATIONS
37	Feasibility of HER2-Targeted Therapy in Advanced Biliary Tract Cancer: A Prospective Pilot Study of Trastuzumab Biosimilar in Combination with Gemcitabine Plus Cisplatin. <i>Cancers</i> , 2021, 13, 161.	1.7	17
38	Spatial Distribution and Prognostic Implications of Tumor-Infiltrating FoxP3- CD4+ T Cells in Biliary Tract Cancer. <i>Cancer Research and Treatment</i> , 2021, 53, 162-171.	1.3	11
39	Clinical outcomes with multikinase inhibitors after progression on first-line atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: A multinational, multicenter retrospective study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 272-272.	0.8	4
40	Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study. <i>Lancet Oncology</i> , The, 2021, 22, 1560-1572.	5.1	118
41	Real-world data analysis of patients with cancer of unknown primary. <i>Scientific Reports</i> , 2021, 11, 23074.	1.6	13
42	A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1&sup4, as a single dose and multiple doses in patients with solid malignancies. <i>Investigational New Drugs</i> , 2020, 38, 445-456.	1.2	16
43	Effects of Subsequent Systemic Anticancer Medication Following First-Line Lenvatinib: A Post Hoc Responder Analysis from the Phase 3 REFLECT Study in Unresectable Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2020, 9, 93-104.	4.2	60
44	Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 193-202.	0.8	1,255
45	FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592095329.	1.4	21
46	Effectiveness and Safety of Nivolumab in Child&Pugh B Patients with Hepatocellular Carcinoma: A Real-World Cohort Study. <i>Cancers</i> , 2020, 12, 1968.	1.7	40
47	Lymphocyte to&monocyte ratio-based nomogram for predicting outcomes of hepatocellular carcinoma treated with sorafenib. <i>Hepatology International</i> , 2020, 14, 776-787.	1.9	15
48	Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial. <i>ESMO Open</i> , 2020, 5, e000714.	2.0	51
49	Real-World Efficacy and Safety of Lenvatinib in Korean Patients with Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Analysis. <i>Liver Cancer</i> , 2020, 9, 613-624.	4.2	45
50	Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biomarker analysis. <i>British Journal of Cancer</i> , 2020, 123, 362-368.	2.9	29
51	Reduced and Normalized Carbohydrate Antigen 19-9 Concentrations after Neoadjuvant Chemotherapy Have Comparable Prognostic Performance in Patients with Borderline Resectable and Locally Advanced Pancreatic Cancer. <i>Journal of Clinical Medicine</i> , 2020, 9, 1477.	1.0	8
52	Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. <i>Lancet Oncology</i> , The, 2020, 21, 808-820.	5.1	371
53	Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092342.	1.4	14
54	Regorafenib in patients with advanced Child&Pugh B hepatocellular carcinoma: A multicentre retrospective study. <i>Liver International</i> , 2020, 40, 2544-2552.	1.9	32

#	ARTICLE	IF	CITATIONS
55	Rivaroxaban <i>Versus</i> Low-molecular-weight Heparin for Venous Thromboembolism in Advanced Upper Gastrointestinal Tract and Hepatopancreatobiliary Cancer. <i>In Vivo</i> , 2020, 34, 829-837.	0.6	10
56	Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens. <i>BMC Cancer</i> , 2020, 20, 633.	1.1	19
57	Regorafenib in previously treated advanced hepatocellular carcinoma: Impact of prior immunotherapy and adverse events. <i>Liver International</i> , 2020, 40, 2263-2271.	1.9	26
58	Tumour-to-liver ratio determined by [68Ga]Ga-DOTA-TOC PET/CT as a prognostic factor of lanreotide efficacy for patients with well-differentiated gastroenteropancreatic-neuroendocrine tumours. <i>EJNMMI Research</i> , 2020, 10, 63.	1.1	22
59	Longitudinal and personalized detection of circulating tumor DNA (ctDNA) for monitoring efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 3531-3531.	0.8	20
60	Effect of pembrolizumab (pembro) on hepatitis B viral (HBV) load and aminotransferase (ALT) levels in patients (pts) with advanced hepatocellular carcinoma (aHCC) in KEYNOTE-224 and KEYNOTE-240.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4587-4587.	0.8	2
61	Phase III study of pembrolizumab (pembro) versus best supportive care (BSC) for second-line therapy in advanced hepatocellular carcinoma (aHCC): KEYNOTE-240 Asian subgroup.. <i>Journal of Clinical Oncology</i> , 2020, 38, 526-526.	0.8	5
62	Randomized Phase III Study of FOLFOX Alone and with Pegilodexakin as Second-line Therapy in Patients with Metastatic Pancreatic Cancer (SEQUOIA).. <i>Journal of Clinical Oncology</i> , 2020, 38, 637-637.	0.8	16
63	Efficacy and safety of second-line nab-paclitaxel plus gemcitabine (nab-P+GEM) after progression on first-line FOLFIRINOX in advanced pancreatic ductal adenocarcinoma (PDAC): Multicenter retrospective analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, 689-689.	0.8	1
64	Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma. <i>Cancer Research and Treatment</i> , 2020, 52, 254-262.	1.3	14
65	Efficacy and Safety of Pembrolizumab in Patients with Refractory Advanced Biliary Tract Cancer: Tumor Proportion Score as a Potential Biomarker for Response. <i>Cancer Research and Treatment</i> , 2020, 52, 594-603.	1.3	55
66	Subsequent anticancer procedures following first-line lenvatinib (LEN): A post hoc analysis from the phase III REFLECT study in unresectable hepatocellular carcinoma (uHCC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 520-520.	0.8	2
67	Efficacy and safety of lenvatinib (LEN) in Korean patients (pts) with advanced hepatocellular carcinoma (aHCC): Multicenter retrospective analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, 490-490.	0.8	0
68	Efficacy and safety of mFOLFIRINOX in patients with borderline resectable and locally advanced unresectable pancreatic cancer: Intention-to-treat population analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, 720-720.	0.8	0
69	Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma. <i>Cancer Research and Treatment</i> , 2019, 51, 510-518.	1.3	39
70	Feasibility, safety, and adequacy of research biopsies for cancer clinical trials at an academic medical center. <i>PLoS ONE</i> , 2019, 14, e0221065.	1.1	11
71	Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker. <i>European Journal of Cancer</i> , 2019, 120, 31-39.	1.3	58
72	Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591987112.	1.4	27

#	ARTICLE	IF	CITATIONS
73	Stereotactic body radiation therapy for locally advanced pancreatic cancer. <i>PLoS ONE</i> , 2019, 14, e0214970.	1.1	45
74	Clinical Outcomes of Conversion Surgery after Neoadjuvant Chemotherapy in Patients with Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer: A Single-Center, Retrospective Analysis. <i>Cancers</i> , 2019, 11, 278.	1.7	31
75	Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib. <i>BMC Cancer</i> , 2019, 19, 292.	1.1	50
76	Efficacy and safety of lanreotide in Korean patients with metastatic, well-differentiated gastroenteropancreatic-neuroendocrine tumors: a retrospective analysis. <i>Investigational New Drugs</i> , 2019, 37, 763-770.	1.2	10
77	An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma. <i>Oncologist</i> , 2019, 24, 747-e218.	1.9	72
78	Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine: implication of inflammation-based scores. <i>Investigational New Drugs</i> , 2019, 37, 584-590.	1.2	13
79	Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3). <i>Gastric Cancer</i> , 2019, 22, 527-535.	2.7	88
80	Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma. <i>Investigational New Drugs</i> , 2019, 37, 567-572.	1.2	44
81	Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4004-4004.	0.8	149
82	Meta-analysis of OS for pancreatic cancer patients receiving 5FU and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy.. <i>Journal of Clinical Oncology</i> , 2019, 37, 202-202.	0.8	3
83	Association between overall survival and adverse events with lenvatinib treatment in patients with hepatocellular carcinoma (REFLECT).. <i>Journal of Clinical Oncology</i> , 2019, 37, 317-317.	0.8	26
84	Subsequent anticancer medication following first-line lenvatinib: A posthoc responder analysis from the phase 3 REFLECT study in unresectable hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 371-371.	0.8	10
85	Alpha fetoprotein (AFP) response and efficacy outcomes in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 423-423.	0.8	7
86	Clinical Benefit of Maintenance Therapy for Advanced Biliary Tract Cancer Patients Showing No Progression after First-Line Gemcitabine Plus Cisplatin. <i>Cancer Research and Treatment</i> , 2019, 51, 901-909.	1.3	17
87	Multicenter retrospective analysis for efficacy and safety of liposomal irinotecan (nal-IRI) plus 5-FU/leucovorin (5-FU/LV) after progression on gemcitabine-based therapy in Korean patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): A study by Korean Cancer Study Group (KCSG).. <i>Journal of Clinical Oncology</i> , 2019, 37, 344-344.	0.8	1
88	Phase II trial of preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by postoperative gemcitabine (GEM) in patients (pts) with borderline resectable pancreatic ductal adenocarcinomas (BR-PDAC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 342-342.	0.8	0
89	Neoadjuvant chemotherapy followed by surgery versus upfront surgery in patients with borderline resectable and locally advanced unresectable pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 312-312.	0.8	0
90	DNA damage repair (DDR) gene alterations as a predictive biomarker for response to platinum-containing chemotherapy in advanced biliary tract cancer (BTC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4078-4078.	0.8	0

#	ARTICLE	IF	CITATIONS
91	Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis. <i>Investigational New Drugs</i> , 2018, 36, 732-741.	1.2	87
92	Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion. <i>JAMA Oncology</i> , 2018, 4, 661.	3.4	311
93	A Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2018, 7, 165-178.	4.2	23
94	Prognostic Implication of Inflammation-based Prognostic Scores in Patients with Intrahepatic Cholangiocarcinoma Treated with First-line Gemcitabine plus Cisplatin. <i>Investigational New Drugs</i> , 2018, 36, 496-502.	1.2	9
95	Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category for genetic testing. <i>Investigational New Drugs</i> , 2018, 36, 163-169.	1.2	13
96	Absence of antitumor effects of metformin in sorafenib-treated patients with hepatocellular carcinoma recurrence after hepatic resection and liver transplantation. <i>Annals of Hepato-biliary-pancreatic Surgery</i> , 2018, 22, 297.	0.1	11
97	Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patients. <i>Investigational New Drugs</i> , 2018, 36, 1072-1084.	1.2	32
98	Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2018, 379, 54-63.	13.9	1,677
99	Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with <i>c-RAS</i> -Mutated Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 4650-4661.	3.2	63
100	A Prospective Randomized Comparison of a Covered Metallic Ureteral Stent and a Double-J Stent for Malignant Ureteral Obstruction. <i>Korean Journal of Radiology</i> , 2018, 19, 606.	1.5	15
101	Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study. <i>British Journal of Cancer</i> , 2018, 119, 19-26.	2.9	28
102	Prognostic implications of hepatitis B virus infection in intrahepatic cholangiocarcinoma treated with first-line gemcitabine plus cisplatin. <i>International Journal of Biological Markers</i> , 2018, 33, 432-438.	0.7	2
103	Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase 3 CELESTIAL trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4019-4019.	0.8	10
104	Safety and clinical activity of 1L atezolizumab + bevacizumab in a phase Ib study in hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4074-4074.	0.8	87
105	Phase I dose-finding study of OPB-111077, a novel STAT3 inhibitor, in patients with advanced hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4078-4078.	0.8	3
106	Outcomes in patients (pts) who had received sorafenib (S) as the only prior systemic therapy in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4088-4088.	0.8	6
107	Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase III CELESTIAL trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 207-207.	0.8	62
108	Independent imaging review (IIR) results in a phase 3 trial of lenvatinib (LEN) versus sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 345-345.	0.8	1

#	ARTICLE	IF	CITATIONS
109	Phase II Study of Induction Chemotherapy with Docetaxel, Capecitabine, and Cisplatin Plus Bevacizumab for Initially Unresectable Gastric Cancer with Invasion of Adjacent Organs or Paraaortic Lymph Node Metastasis. <i>Cancer Research and Treatment</i> , 2018, 50, 518-529.	1.3	10
110	Prognosis of Pancreatic Cancer Patients with Synchronous or Metachronous Malignancies from Other Organs Is Better than Those with Pancreatic Cancer Only. <i>Cancer Research and Treatment</i> , 2018, 50, 1175-1185.	1.3	17
111	Multicenter Phase II Study of Oxaliplatin, Irinotecan, and S-1 as First-line Treatment for Patients with Recurrent or Metastatic Biliary Tract Cancer. <i>Cancer Research and Treatment</i> , 2018, 50, 1324-1330.	1.3	21
112	Efficacy of nab-paclitaxel plus gemcitabine (AG) vs. FOLFIRINOX as first line chemotherapy for metastatic pancreatic cancer (mPC): Real world experiences.. <i>Journal of Clinical Oncology</i> , 2018, 36, 354-354.	0.8	1
113	Clinical benefit of maintenance therapy for patients with advanced biliary tract cancer without progression on first-line gemcitabine plus cisplatin.. <i>Journal of Clinical Oncology</i> , 2018, 36, 357-357.	0.8	0
114	Effect of transarterial chemoembolization plus external beam radiotherapy on survival of patients with hepatocellular carcinoma showing macroscopic vascular invasion compared with sorafenib: A randomized trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 210-210.	0.8	0
115	Associations between CYP2A6 polymorphisms and outcomes of adjuvant S-1 chemotherapy in patients with curatively resected gastric cancer. <i>Gastric Cancer</i> , 2017, 20, 146-155.	2.7	11
116	Phase 2 study of adjuvant chemotherapy with docetaxel, capecitabine, and cisplatin in patients with curatively resected stage III&IV gastric cancer. <i>Gastric Cancer</i> , 2017, 20, 182-189.	2.7	6
117	Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients. <i>British Journal of Cancer</i> , 2017, 116, 561-567.	2.9	48
118	A Phase I/IIa Study of DHP107, a Novel Oral Paclitaxel Formulation, in Patients with Advanced Solid Tumors or Gastric Cancer. <i>Oncologist</i> , 2017, 22, 129-e8.	1.9	18
119	Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study. <i>European Journal of Cancer</i> , 2017, 81, 17-25.	1.3	64
120	Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 209-215.	1.1	64
121	Phase I/II study of a combination of capecitabine, cisplatin, and intraperitoneal docetaxel (XP ID) in advanced gastric cancer patients with peritoneal metastasis. <i>Gastric Cancer</i> , 2017, 20, 970-977.	2.7	13
122	Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 139-146.	1.1	28
123	Clinical outcomes of patients with resectable pancreatic acinar cell carcinoma. <i>Journal of Digestive Diseases</i> , 2017, 18, 480-486.	0.7	14
124	Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma. <i>JAMA Oncology</i> , 2017, 3, 235.	3.4	74
125	Prognostic impact of <i>fibroblast growth factor receptor 2</i> gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced unresectable gastric cancers. <i>Oncotarget</i> , 2017, 8, 33844-33854.	0.8	20
126	Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: Results of GASTric cancer HER2 reassessment study 3 (GASTHER3).. <i>Journal of Clinical Oncology</i> , 2017, 35, 27-27.	0.8	4

#	ARTICLE	IF	CITATIONS
127	Multiplexed gene expression profiling identifies the FGFR4 pathway as a novel biomarker in intrahepatic cholangiocarcinoma. <i>Oncotarget</i> , 2017, 8, 38592-38601.	0.8	21
128	Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen. <i>Oncotarget</i> , 2017, 8, 46337-46347.	0.8	35
129	Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access Program. <i>Cancer Research and Treatment</i> , 2017, 49, 350-357.	1.3	23
130	Efficacy of Chemotherapy in Patients with Unresectable or Metastatic Pancreatic Acinar Cell Carcinoma: Potentially Improved Efficacy with Oxaliplatin-Containing Regimen. <i>Cancer Research and Treatment</i> , 2017, 49, 759-765.	1.3	31
131	Postoperative Radiotherapy for Pancreatic Cancer with Microscopically-positive Resection Margin. <i>Anticancer Research</i> , 2017, 37, 755-764.	0.5	3
132	Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary cancer after failure of gemcitabine plus cisplatin: Retrospective analysis of 321 patients.. <i>Journal of Clinical Oncology</i> , 2017, 35, 425-425.	0.8	0
133	Second-Line Irinotecan, Leucovorin, and 5-Fluorouracil for Gastric Cancer Patients after Failed Docetaxel and S-1. <i>Gastroenterology Research and Practice</i> , 2016, 2016, 1-6.	0.7	4
134	Study protocol of the Asian XELIRI Project (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab. <i>Chinese Journal of Cancer</i> , 2016, 35, 102.	4.9	12
135	Association of nutritional status-related indices and chemotherapy-induced adverse events in gastric cancer patients. <i>BMC Cancer</i> , 2016, 16, 900.	1.1	67
136	Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2016, 65, 289-295.	1.8	89
137	Vorinostat in combination with capecitabine plus cisplatin as a first-line chemotherapy for patients with metastatic or unresectable gastric cancer: phase II study and biomarker analysis. <i>British Journal of Cancer</i> , 2016, 114, 1185-1190.	2.9	35
138	Risk factors for selection of patients at high risk of recurrence or death after complete surgical resection in stage I gastric cancer. <i>Gastric Cancer</i> , 2016, 19, 226-233.	2.7	32
139	Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1). <i>European Journal of Cancer</i> , 2016, 53, 42-50.	1.3	76
140	Impact of imatinib rechallenge on health-related quality of life in patients with TKI-refractory gastrointestinal stromal tumours: Sub-analysis of the placebo-controlled, randomised phase III trial (RIGHT). <i>European Journal of Cancer</i> , 2016, 52, 201-208.	1.3	8
141	Phase II study of docetaxel, oxaliplatin, and S-1 therapy in patients with metastatic gastric cancer. <i>Gastric Cancer</i> , 2016, 19, 579-585.	2.7	11
142	First-in-human study of HM95573, a novel oral RAF inhibitor, in patients with solid tumors.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2570-2570.	0.8	4
143	Efficacy and safety findings from DREAM: A phase III study of DHP107 (oral paclitaxel) vs IV paclitaxel in patients with gastric cancer after failure of first-line chemotherapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4016-4016.	0.8	3
144	Tolerability and activity of tepotinib in Asian patients with advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 4072-4072.	0.8	2

#	ARTICLE	IF	CITATIONS
145	Clinical significance of MET amplification in metastatic or locally advanced gastric cancer treated with first-line fluoropyrimidine and platinum (FP) combination chemotherapy.. Journal of Clinical Oncology, 2016, 34, 69-69.	0.8	1
146	Role of transarterial chemoembolization in relation with sorafenib for patients with advanced hepatocellular carcinoma. Oncotarget, 2016, 7, 74303-74313.	0.8	19
147	Second-line ramucirumab therapy for advanced hepatocellular carcinoma (REACH): an East Asian and non-East Asian subgroup analysis. Oncotarget, 2016, 7, 75482-75491.	0.8	18
148	Apoptosis of Hepatitis B Virus-expressing Liver Tumor Cells Induced by a High Concentration of Nucleos(t)ide Analogue. Anticancer Research, 2016, 36, 6059-6070.	0.5	6
149	Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha-Expressing Mutated Gastrointestinal Stromal Tumors. Cancer Research and Treatment, 2016, 48, 546-552.	1.3	38
150	Severe Imatinib-Associated Skin Rash in Gastrointestinal Stromal Tumor Patients: Management and Clinical Implications. Cancer Research and Treatment, 2016, 48, 162-170.	1.3	13
151	Real-Life Experience of Sorafenib Treatment for Hepatocellular Carcinoma in Korea: From GIDEON Data. Cancer Research and Treatment, 2016, 48, 1243-1252.	1.3	20
152	Efficacy of chemotherapy in patients with pancreatic acinar cell carcinoma.. Journal of Clinical Oncology, 2016, 34, 308-308.	0.8	0
153	An interim safety analysis of hepatocellular carcinoma patients administrating oral vitamin K with or without sorafenib. Korean Journal of Hepato-biliary-pancreatic Surgery, 2015, 19, 1.	1.0	12
154	FGFR2 Assessment in Gastric Cancer Using Quantitative Real-Time Polymerase Chain Reaction, Fluorescent In Situ Hybridization, and Immunohistochemistry. American Journal of Clinical Pathology, 2015, 143, 865-872.	0.4	18
155	Comparison of Chemoembolization with and without Radiation Therapy and Sorafenib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Propensity Score Analysis. Journal of Vascular and Interventional Radiology, 2015, 26, 320-329.e6.	0.2	75
156	Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncology, The, 2015, 16, 859-870.	5.1	699
157	Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study. Journal of Hepatology, 2015, 63, 896-904.	1.8	44
158	Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer. European Journal of Cancer, 2015, 51, 482-488.	1.3	103
159	Prognostic Relevance of p53 Overexpression in Gastrointestinal Stromal Tumors of the Small Intestine: Potential Implication for Adjuvant Treatment with Imatinib. Annals of Surgical Oncology, 2015, 22, 362-369.	0.7	4
160	Efficacy and safety of nintedanib versus sorafenib in Asian patients with advanced hepatocellular carcinoma (HCC): A randomized phase II trial.. Journal of Clinical Oncology, 2015, 33, 339-339.	0.8	7
161	Efficacy and safety of regorafenib in Korean patients with advanced gastrointestinal stromal tumor after failure of imatinib and sunitinib: A multicenter study based on the management access program.. Journal of Clinical Oncology, 2015, 33, 175-175.	0.8	0
162	Phase II study of neoadjuvant chemotherapy with docetaxel, capecitabine, cisplatin and bevacizumab for initially unresectable gastric cancer with invasion of adjacent organs or paraaortic lymph node metastasis.. Journal of Clinical Oncology, 2015, 33, e15060-e15060.	0.8	0

#	ARTICLE	IF	CITATIONS
163	A phase III study to compare efficacy and safety of DHP107 (oral paclitaxel) versus IV paclitaxel in patients with metastatic or recurrent gastric cancer after failure of first-line chemotherapy (DREAM).. Journal of Clinical Oncology, 2015, 33, TPS4138-TPS4138.	0.8	0
164	Efficacy and safety of nintedanib (N) versus sorafenib (S) in Caucasian and Asian patients with advanced hepatocellular carcinoma (HCC): Pooled analysis of two randomized phase II trials.. Journal of Clinical Oncology, 2015, 33, 4074-4074.	0.8	0
165	Phase I/II study of a combination of capecitabine, cisplatin, and intraperitonealdocetaxel (XP ID) in patients with advanced gastric cancer with peritoneal metastasis.. Journal of Clinical Oncology, 2015, 33, 4026-4026.	0.8	0
166	Phase II study of everolimus as a salvage treatment after failure of fluoropyrimidine and platinum in patients with metastatic gastric cancer positive for pS6Ser240/4 expression.. Journal of Clinical Oncology, 2015, 33, 4057-4057.	0.8	0
167	Sorafenib inhibits migration and invasion of hepatocellular carcinoma cells through suppression of matrix metalloproteinase expression. Anticancer Research, 2015, 35, 1967-76.	0.5	23
168	Synergistic effect of sorafenib and vitamin K on suppression of hepatocellular carcinoma cell migration and metastasis. Anticancer Research, 2015, 35, 1985-95.	0.5	18
169	Prognostic significance of neuroendocrine components in gastric carcinomas. European Journal of Cancer, 2014, 50, 2802-2809.	1.3	52
170	Randomized phase II trial of intravenous RO5137382/GC33 at 1600 mg every other week and placebo in previously treated patients with unresectable advanced hepatocellular carcinoma (HCC); Tj ETQq0 0 0 rgBT /Overlook10 Tf 505457 Td (0.8	0
171	A phase I dose escalation study to evaluate safety and tolerability of cabazitaxel (Cbz) as a single agent in patients (pts) with advanced gastric adenocarcinoma who have failed prior chemotherapy (CT) regimens (GASTANA).. Journal of Clinical Oncology, 2014, 32, 141-141.	0.8	0
172	A Study on Vascular Pain Due to Gemcitabine and According to Clinical Factors. Asian Oncology Nursing, 2013, 13, 210.	0.2	0
173	Randomized phase III trial of imatinib (IM) rechallenge versus placebo (PL) in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) after failure of at least both IM and sunitinib (SU): RIGHT study.. Journal of Clinical Oncology, 2013, 31, LBA10502-LBA10502.	0.8	5
174	A phase I dose-finding study of everolimus in combination with capecitabine and oxaliplatin (XELOX) as the first-line chemotherapy for patients with advanced gastric cancer.. Journal of Clinical Oncology, 2013, 31, 86-86.	0.8	0
175	Randomized phase III trial of imatinib (IM) rechallenge versus placebo in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) after failure of at least both IM and sunitinib (SU): Right study.. Journal of Clinical Oncology, 2013, 31, LBA10502-LBA10502.	0.8	4
176	The role of surgical resection following imatinib treatment in patients with metastatic or recurrent GIST.. Journal of Clinical Oncology, 2013, 31, 10550-10550.	0.8	0
177	Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study. Annals of Hematology, 2012, 91, 543-551.	0.8	50
178	A phase II study of tivantinib monotherapy in patients with previously treated advanced or recurrent gastric cancer.. Journal of Clinical Oncology, 2012, 30, 4082-4082.	0.8	10
179	The role of surgical cytoreduction before imatinib therapy in patients with advanced GIST.. Journal of Clinical Oncology, 2012, 30, 10093-10093.	0.8	0
180	Pharmacokinetics of escalated dose of imatinib in patients with advanced gastrointestinal stromal tumors.. Journal of Clinical Oncology, 2012, 30, 10085-10085.	0.8	0

#	ARTICLE	IF	CITATIONS
181	Phase Ib dose-escalation study of a phase II randomized trial to assess the safety and tolerability of tigatuzumab (CS-1008) in combination with sorafenib in patients (pts) with advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2012, 30, e14617-e14617.	0.8	0
182	Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function. Cancer Chemotherapy and Pharmacology, 2011, 68, 1641-1642.	1.1	1
183	Nongastric marginal zone B-cell lymphoma: A prognostic model from a retrospective multicenter study. Cancer Letters, 2007, 258, 90-97.	3.2	19
184	Nongastric marginal zone B-cell lymphoma: Analysis of 247 cases. American Journal of Hematology, 2007, 82, 446-452.	2.0	41
185	Intestinal marginal zone B-cell lymphoma of MALT type: clinical manifestation and outcome of a rare disease. European Journal of Haematology, 2007, 79, 287-291.	1.1	14
186	Nodal marginal zone B-cell lymphoma: analysis of 36 cases. Clinical presentation and treatment outcomes of nodal marginal zone B-cell lymphoma. Annals of Hematology, 2006, 85, 781-786.	0.8	43